Contact
searchSearch
HMP Global

Pharmacy Learning Network

PharmLaw

PharmLaw
North Carolina Reaches $11 Million EpiPen Settlement Over Pricing Practices
05/06/2026
Grace Taylor, MS, MA
North Carolina secured an $11 million settlement with Mylan over alleged EpiPen pricing and rebate practices that impacted Medicaid and state health plan costs.
North Carolina secured an $11 million settlement with Mylan over alleged EpiPen pricing and rebate practices that impacted Medicaid and state health plan costs.
North Carolina secured an $11...
05/06/2026
Pharmacy Learning Network
PharmLaw
Purdue Pharma Sentenced in Federal Opioid Case, Finalizing Fraud and Kickback Conspiracy Resolution
04/29/2026
Grace Taylor, MS, MA
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal...
04/29/2026
Pharmacy Learning Network
PharmLaw
Drug Lobby Challenges Washington State 340B Pharmacy Law
04/27/2026
Grace Taylor, MS, MA
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade...
04/27/2026
Pharmacy Learning Network
PharmLaw
Executive Order Targets Accelerated Development and Access Pathways for Psychedelic Therapies in Mental Health
04/21/2026
Hannah Musick
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs...
04/21/2026
Pharmacy Learning Network
PharmLaw
CMS Proposes Sweeping Prior Authorization Reforms for Drugs, Expanding Transparency and Electronic Requirements
04/15/2026
Hannah Musick
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The Centers for Medicare & Medicaid Services has proposed sweeping reforms to modernize prior authorization for drugs, introducing faster decision timelines, expanded electronic requirements, and new transparency measures that could...
The Centers for Medicare &...
04/15/2026
Pharmacy Learning Network

FDA Recalls

News
Lactated Ringer’s Injections Recalled Due to the Presence of Particulate Matter
05/21/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall on Lactated Ringer’s injections USP, 1000 mL due to the presence of particulate matter, affecting 95 412 containers.
The US Food and Drug Administration (FDA) has issued a Class I recall on Lactated Ringer’s injections USP, 1000 mL due to the presence of particulate matter, affecting 95 412 containers.
The US Food and Drug...
05/21/2026
Pharmacy Learning Network
News
Preservative-Free Lubricant Eye Drops Recalled Due to Lack of Sterility Assurance
05/21/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall on Oasis Tears PF, preservative-free lubricant eye drops, due to the lack of assurance of sterility.
The US Food and Drug Administration (FDA) has issued a Class II recall on Oasis Tears PF, preservative-free lubricant eye drops, due to the lack of assurance of sterility.
The US Food and Drug...
05/21/2026
Pharmacy Learning Network
News
Buprenorphine Hydrochloride Injections Recalled Due to the Presence of Particulate Matter
05/21/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for buprenorphine hydrochloride injections due to the presence of particulate matter, which has been identified as buprenorphine base matter.
The US Food and Drug Administration (FDA) has issued a Class II recall for buprenorphine hydrochloride injections due to the presence of particulate matter, which has been identified as buprenorphine base matter.
The US Food and Drug...
05/21/2026
Pharmacy Learning Network
News
Duloxetine Delayed-Release Capsules Recalled Due to CGMP Deviations
05/14/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) issued a Class II recall on duloxetine delayed-release capsules due to deviations in Current Good Manufacturing Practice (CGMP) regulations.
The US Food and Drug Administration (FDA) issued a Class II recall on duloxetine delayed-release capsules due to deviations in Current Good Manufacturing Practice (CGMP) regulations.
The US Food and Drug...
05/14/2026
Pharmacy Learning Network
News
Enalapril Maleate Tablets Recalled Due to Failed Impurities/Degradation Specifications
05/14/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall on enalapril maleate tablets for failed impurities/degradation specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall on enalapril maleate tablets for failed impurities/degradation specifications.
The US Food and Drug...
05/14/2026
Pharmacy Learning Network

In the News

News
Lactated Ringer’s Injections Recalled Due to the Presence of Particulate Matter
05/21/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall on Lactated Ringer’s injections USP, 1000 mL due to the presence of particulate matter, affecting 95 412 containers.
The US Food and Drug Administration (FDA) has issued a Class I recall on Lactated Ringer’s injections USP, 1000 mL due to the presence of particulate matter, affecting 95 412 containers.
The US Food and Drug...
05/21/2026
Pharmacy Learning Network
News
Preservative-Free Lubricant Eye Drops Recalled Due to Lack of Sterility Assurance
05/21/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall on Oasis Tears PF, preservative-free lubricant eye drops, due to the lack of assurance of sterility.
The US Food and Drug Administration (FDA) has issued a Class II recall on Oasis Tears PF, preservative-free lubricant eye drops, due to the lack of assurance of sterility.
The US Food and Drug...
05/21/2026
Pharmacy Learning Network
News
Buprenorphine Hydrochloride Injections Recalled Due to the Presence of Particulate Matter
05/21/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for buprenorphine hydrochloride injections due to the presence of particulate matter, which has been identified as buprenorphine base matter.
The US Food and Drug Administration (FDA) has issued a Class II recall for buprenorphine hydrochloride injections due to the presence of particulate matter, which has been identified as buprenorphine base matter.
The US Food and Drug...
05/21/2026
Pharmacy Learning Network
News
Duloxetine Delayed-Release Capsules Recalled Due to CGMP Deviations
05/14/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) issued a Class II recall on duloxetine delayed-release capsules due to deviations in Current Good Manufacturing Practice (CGMP) regulations.
The US Food and Drug Administration (FDA) issued a Class II recall on duloxetine delayed-release capsules due to deviations in Current Good Manufacturing Practice (CGMP) regulations.
The US Food and Drug...
05/14/2026
Pharmacy Learning Network
News
Enalapril Maleate Tablets Recalled Due to Failed Impurities/Degradation Specifications
05/14/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall on enalapril maleate tablets for failed impurities/degradation specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall on enalapril maleate tablets for failed impurities/degradation specifications.
The US Food and Drug...
05/14/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use